UBS AM’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

UBS AM’s Portfolio ZYNE Stock Details ZYNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-272	Closed	-$2.65K	–	2833
2018 Q2	$2.65K	Buy	+272	New	+$2.79K	﹤0.01%	2739

Other funds holding ZYNE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FTIOP

Fiduciary Trust International of Pennsylvania Radnor, Pennsylvania $2.14B AUM 3.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

UBS AM's ZYNE Position: Q3 2018 in Review

UBS AM sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q3 2018, closing a stake of 272 shares — an estimated $2.65K sold.

UBS AM first reported a position in ZYNE in Q2 2018 and held it in 1 quarter. The position peaked at $2.65K in Q2 2018. 66 funds tracked by Wall St. Rank hold ZYNE as of Q3 2018.

UBS AM reported no remaining Zynerba Pharmaceuticals, Inc position as of Q3 2018 after selling out during the quarter.
UBS AM sold 272 Zynerba Pharmaceuticals, Inc shares in Q3 2018, an estimated $2.65K.
UBS AM first reported a position in Zynerba Pharmaceuticals, Inc in Q2 2018 and held it in 1 quarter.
UBS AM's Zynerba Pharmaceuticals, Inc position peaked at $2.65K in Q2 2018.
66 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q3 2018.

Based on UBS AM's 13F filing for Q3 2018, filed 14 Nov 2018.